A family history of atherosclerotic cardiovascular disease (ASCVD) may be a useful indicator of elevated Lp(a) level and the need for Lp(a) targeted risk assessment. This is the conclusion from an analysis of data on 4,244 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) who had Lp(a) measurements and detailed family history information from completed questionnaires.
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)